• CE Melphalan is being developed as a novel version of the well-established conditioning treatment in autologous transplant for patients with multiple myeloma. CE Melphalan does not contain propylene glycol, an ingredient in currently available products which has been associated with renal and cardiac side effects.
• In its pivotal trial, CE Melphalan met its primary endpoint. The improved stability profile of CE Melphalan could lead to rapid adoption in the transplant conditioning market.
• The company expects to file an NDA in the 3rd quarter and plans to

 …

Little Rock, Arkansas (Press Release) - World-renowned multiple myeloma researcher and clinician Gareth Morgan, M.D., Ph.D., today was named director of the University of Arkansas for Medical Sciences (UAMS) Myeloma Institute for Research and Therapy (MIRT).

Morgan, who is cur­rently a clinician and researcher with the Myeloma UK Research Centre at the Institute of Cancer Research in London, will begin at UAMS on a full-time basis in July. He is a director of Myeloma UK, a respected patient organization, as well as a member of the Scientific Board of the Inter­na­tional Myeloma Foundation, Scientific …

London (Press Release) - People newly diag­nosed with the blood cancer multiple myeloma will now be guaranteed access to bor­tez­o­mib, also known as Velcade.

Multiple myeloma develops from cells in the bone marrow. Almost 4,000 cases are diag­nosed every year in the UK. There is cur­rently no cure; there are only treat­ments to stop its progress and relieve symp­toms.

NICE's independent experts examined the use of bor­tez­o­mib for newly diag­nosed patients who are eli­gible for high-dose chemo­ther­apy and who are suitable for bone marrow trans­plant (haematopoietic stem cell trans­plan­ta­tion). The experts were looking …

- 4/12 patients (33%) showed evi­dence of stable disease; 2 patients for more than 130 days
- A clin­i­cally-relevant mean time to next ther­apy of 51 days
- PAT-SM6 specifically targets myeloma tumour cells in vivo and stimulates signifcant immune responses
- All dose levels admin­istered were safe with no adverse events observed
- No evi­dence of immunogenicity; PK analysis showed PAT-SM6 to have a half-life of 7 hrs

Melbourne, Australia (Press Release) - Patrys Limited (ASX: PAB; “the Company”), a clin­i­cal stage bio­tech­nology com­pany, is pleased to announce the final results from …

NICE, the health­care guidance body, has issued new draft guidance on the use of lena­lido­mide (Revlimid, Celgene) for treating the blood cancer multiple myeloma after one prior treat­ment with bor­tez­o­mib. With the current in­for­ma­tion avail­able, the committee's pre­lim­i­nary guidance (now being issued for consultation) does not recommend lena­lido­mide for this indi­ca­tion [1].

Multiple myeloma is a type of cancer that develops from cells in the bone marrow and there is cur­rently no cure for the disease, only treat­ments to stop the progress of the con­di­tion and help relieve symp­toms. Although the choice …

- First Phase III study of dara­tu­mu­mab
- Patient recruitment to start in the coming months

Copenhagen (Press Release) - Genmab A/S (OMX: GEN) announced today that its partner, Janssen Biotech, Inc. ("Janssen") will start a Phase III study of dara­tu­mu­mab in re­lapsed or refractory multiple myeloma.  The study will compare dara­tu­mu­mab in com­bi­na­tion with lena­lido­mide and dexa­metha­sone to lena­lido­mide and dexa­metha­sone alone.

"The dara­tu­mu­mab devel­op­ment pro­gram is progressing very well.  We are extremely pleased to be able to announce that this study eval­u­ating dara­tu­mu­mab in com­bi­na­tion with a core multiple myeloma treat­ment regime will ini­ti­ate patient recruitment in the coming months," said Jan van de Winkel, Ph.D., …

-- Company Presenting Today at Biocom’s Global Life Science Partnering Conference --

Toronto and San Diego (Press Release) - Triphase Accelerator Corpo­ra­tion today announced that marizomib, its novel, potent pro­te­a­some inhibitor, has been granted orphan drug desig­na­tion by the U.S. Food and Drug Admin­istra­tion (FDA)'s Office of Orphan Products Development for the treat­ment of multiple myeloma. The orphan drug desig­na­tion will provide Triphase with 7-year market­ing exclusivity for marizomib and other benefits upon FDA approval.

“We are pleased that the FDA has granted orphan drug desig­na­tion for the de­vel­op­ment of …